BRPI0814644A2 - Anticorpos para cd200 e usos destes na inibição de respostas imunes. - Google Patents
Anticorpos para cd200 e usos destes na inibição de respostas imunes.Info
- Publication number
- BRPI0814644A2 BRPI0814644A2 BRPI0814644-6A2A BRPI0814644A BRPI0814644A2 BR PI0814644 A2 BRPI0814644 A2 BR PI0814644A2 BR PI0814644 A BRPI0814644 A BR PI0814644A BR PI0814644 A2 BRPI0814644 A2 BR PI0814644A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- inhibiting immune
- answers
- immune answers
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96202207P | 2007-07-25 | 2007-07-25 | |
| PCT/US2008/009037 WO2009014745A1 (en) | 2007-07-25 | 2008-07-25 | Antibodies to cd200 and uses thereof in inhibiting immune responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0814644A2 true BRPI0814644A2 (pt) | 2015-01-27 |
Family
ID=40001380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0814644-6A2A BRPI0814644A2 (pt) | 2007-07-25 | 2008-07-25 | Anticorpos para cd200 e usos destes na inibição de respostas imunes. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | USRE46323E1 (enExample) |
| EP (1) | EP2178561A1 (enExample) |
| JP (4) | JP2010534243A (enExample) |
| KR (1) | KR20100041849A (enExample) |
| AU (1) | AU2008279619B2 (enExample) |
| BR (1) | BRPI0814644A2 (enExample) |
| CA (1) | CA2697159C (enExample) |
| MX (1) | MX2010000981A (enExample) |
| WO (1) | WO2009014745A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534243A (ja) * | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２００に対する抗体および免疫応答への使用 |
| NZ601580A (en) * | 2010-02-11 | 2014-11-28 | Alexion Pharma Inc | Therapeutic methods using anti-cd200 antibodies |
| TW201244737A (en) | 2011-02-03 | 2012-11-16 | Alexion Pharma Inc | Use of an anti-CD200 antibody for prolonging the survival of allografts |
| DK3150632T3 (en) | 2011-06-10 | 2020-04-27 | Canada Minister Nat Defence | ANTI-RICIN ANTIBODIES AND APPLICATIONS THEREOF |
| US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| US9737598B2 (en) * | 2014-06-30 | 2017-08-22 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| US20170296623A1 (en) * | 2014-12-17 | 2017-10-19 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
| AU2016349897B2 (en) | 2015-11-03 | 2021-11-04 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018102594A1 (en) * | 2016-12-01 | 2018-06-07 | Alexion Pharmaceuticals, Inc. | Methods of treating solid tumors with anti-cd200 antibodies |
| KR101968246B1 (ko) * | 2017-04-27 | 2019-04-11 | 서울대학교산학협력단 | 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법 |
| WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
| US12139533B2 (en) | 2017-12-20 | 2024-11-12 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-CD200 antibodies |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| JP7663237B2 (ja) | 2019-01-14 | 2025-04-16 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | がん免疫療法のためのｃｄ２００ａｒリガンド |
| EP4296280A1 (en) | 2022-06-21 | 2023-12-27 | F. Hoffmann-La Roche AG | Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1032662E (pt) * | 1997-11-07 | 2006-07-31 | Trillium Therapeutics Inc | Metodos e composicoes para imunomodulacao. |
| US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| WO2004060295A2 (en) | 2002-12-27 | 2004-07-22 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
| EP2463305B1 (en) * | 2006-01-12 | 2016-05-11 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
| CA2694121C (en) | 2007-07-25 | 2016-06-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
| JP2010534243A (ja) * | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２００に対する抗体および免疫応答への使用 |
-
2008
- 2008-07-25 JP JP2010518230A patent/JP2010534243A/ja active Pending
- 2008-07-25 WO PCT/US2008/009037 patent/WO2009014745A1/en not_active Ceased
- 2008-07-25 CA CA2697159A patent/CA2697159C/en not_active Expired - Fee Related
- 2008-07-25 MX MX2010000981A patent/MX2010000981A/es active IP Right Grant
- 2008-07-25 US US14/080,457 patent/USRE46323E1/en not_active Expired - Fee Related
- 2008-07-25 EP EP08794745A patent/EP2178561A1/en not_active Withdrawn
- 2008-07-25 AU AU2008279619A patent/AU2008279619B2/en not_active Ceased
- 2008-07-25 KR KR1020107003921A patent/KR20100041849A/ko not_active Abandoned
- 2008-07-25 US US12/670,379 patent/US8252285B2/en not_active Ceased
- 2008-07-25 BR BRPI0814644-6A2A patent/BRPI0814644A2/pt not_active IP Right Cessation
-
2012
- 2012-06-26 US US13/533,546 patent/US8637014B2/en active Active
-
2013
- 2013-05-27 JP JP2013110577A patent/JP5926702B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-07 JP JP2015135830A patent/JP2015172090A/ja active Pending
-
2016
- 2016-03-16 JP JP2016052050A patent/JP2016117762A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008279619A1 (en) | 2009-01-29 |
| JP2015172090A (ja) | 2015-10-01 |
| US20120321625A1 (en) | 2012-12-20 |
| JP2010534243A (ja) | 2010-11-04 |
| US8252285B2 (en) | 2012-08-28 |
| CA2697159A1 (en) | 2009-01-29 |
| EP2178561A1 (en) | 2010-04-28 |
| CA2697159C (en) | 2017-02-14 |
| USRE46323E1 (en) | 2017-02-28 |
| US20100291085A1 (en) | 2010-11-18 |
| AU2008279619B2 (en) | 2013-11-14 |
| JP2016117762A (ja) | 2016-06-30 |
| WO2009014745A1 (en) | 2009-01-29 |
| KR20100041849A (ko) | 2010-04-22 |
| MX2010000981A (es) | 2010-05-21 |
| US8637014B2 (en) | 2014-01-28 |
| JP2013163695A (ja) | 2013-08-22 |
| JP5926702B2 (ja) | 2016-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1010540A2 (pt) | "anticorpos especéficos para dkk-1 e seus usos" | |
| BRPI0812005A2 (pt) | anticorpos humanizados para o globulômeros de ab(20-42) e seus usos. | |
| BRPI0819909A2 (pt) | anticorpos antimesotelina e usos dos mesmos | |
| CR10466A (es) | Anticuerpos e inmunoconjugados y sus usos | |
| BRPI1012321A2 (pt) | anticorpos anti-vegf e seus usos | |
| CY2018018I2 (el) | Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα | |
| BRPI1008692A2 (pt) | moléculas de anticorpos tendo especificidade para ox40 humano. | |
| BRPI0815983A2 (en) | humanized anti-cxcr5 antibodies derived from them and their uses | |
| BRPI0906498A2 (pt) | Anticorpo ron e seus usos | |
| HUE037205T2 (hu) | Antitestek, amelyek IL-4-et és/vagy IL-13-at kötnek és alkalmazásaik | |
| DK2176296T3 (da) | Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder. | |
| BRPI0907530A2 (pt) | Anticorpos direcionados à angiopoietina-1 angiopoietina-2 e seus usos | |
| BRPI0821211A2 (pt) | Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo. | |
| BRPI0717638A2 (pt) | Anticorpors e imunoconjugados e usos para os mesmos | |
| IL204159A (en) | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates | |
| CL2014002954A1 (es) | Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos. | |
| BRPI1009455A2 (pt) | anticorpos anti-c40 e usos dos mesmos | |
| BRPI0819598A2 (pt) | anticorpos para o antígeno pcrv da pseudomonas aeruginosa | |
| FI20075278A0 (fi) | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet | |
| BRPI0814003A2 (pt) | Formulações de anticorpo | |
| BR112015003838A2 (pt) | formulações de anticorpo e proteína | |
| PT3339323T (pt) | Anticorpos anti-péptido beta-amilóide n3pglu e seus usos | |
| BRPI0815564A2 (pt) | Anticorpos que inibem a dimerização de c-met e usos dos mesmos. | |
| PL2358756T3 (pl) | Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9 | |
| BRPI0718182A2 (pt) | Oligorribonucleotídeos e seus usos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |